ERBB2 and breast cancer: The APHINITY trial demonstrated that the addition of pertuzumab to adjuvant trastuzumab and CT significantly improved invasive disease-free survival (IDFS) for patients with node-positive HER2-positive BC (hazard ratio 0.76, 95% CI 0.64–0.91), regardless of HR status (hazard ratio 0.73, 95% CI 0.59–0.92 in HR-positive group) [35].